Pharmaceutical companies are increasingly working in partnership with other firms, academia and catapults through collaborative models, in the search to discover and develop new medicines, according to a new Association of the British Pharmaceutical Industry (ABPI) report.
The R&D Sourcebook from the ABPI reveals how this step change toward collaborative working and open innovation—a contrast to the older model of closed corporate research and development labs—continues to support the U.K. economy. The report reveals that the pharmaceutical industry in the U.K. continues to be the highest spending sector on R&D, investing £4.2 billion in 2015—equating to a fifth of all U.K. business research and development spending.
The latest figures demonstrate how pharmaceutical organizations have increased their absolute level of investment in collaborative and outsourced drug discovery in the U.K. over the last five years, with collaborations showing particular strength in oncology and rheumatology. As well as a change to investment models, the sourcebook shows an ongoing change in focus of research into new medicines. Projects and investments increasingly address unmet need, such as rare diseases and cancer, and the U.K. shows great strength in both of these areas.
The sourcebook builds on last year's “Adapting the Innovation Landscape: U.K. Biopharma R&D Sourcebook 2015.” R&D, the way that medicines are developed and the context in which this takes place within the U.K. economy through data and analysis from Clarivate Analytics.
Dr. Virginia Acha, Executive Director—Research, Medical and Innovation at the ABPI, said, "We are in a period of great change, not least with the U.K. embarking on a journey outside of the EU, but also as an industry. It is therefore vital for the future discovery and development of medicines that we continue to collaborate and explore outside of our companies, industry and sector. By focusing on open innovation, this sourcebook aims to shed light on the complex, changing face of the pharmaceutical industry."
The sourcebook considers four key areas:
Global health and the role of biopharma
Investing in innovation
Driving clinical research to deliver medicines
Collaborating for innovation